Monday, September 22, 2014
TKM-EBOLA Making RNAi History
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.
7 comments:
Sorry to hear you are all out of this stock. I told you stop trading this superstar. Buy and hold.
Dirk, you have conveniently forgotten how many lives Gradalis has saved. Oh sorry, that's RNAi therapuetics without a capital T.
I think it's great what TKMR are doing but you should not let your pocket get in the way of your facts.
Have you seen the @bhgreeley message on Ebola? Checkout Bloomberg Businessweek and video.
Brendan Greeley and Caroline Chen uncover that the Ebola drug ZMapp's development was delayed by a Pentagon agency, or as their headline deftly puts it, "How the U.S. Screwed Up in the Fight Against Ebola" (681 shares). " A little-known Pentagon agency had a promising treatment for Ebola — IN 2010 — and failed to act," BW editor Janet Paskin laments.
Are their facts correct or is it possible that USA Gov’t chose Tekmira over ZMapp? The authors seem to be silent to $40MM received by TKMR in research grants from US Dept of Defense.
With UN focus this week on Ebola (following global warming, and terrorism), TKMR public stock could explode.
UN is forming $1 BB effort to fight Ebola.
Dirk,
What do you think is the next catalyst for RGDO? Is there a reason other than their cash on hand to start a small position?
... on Tekmira homepage I can not find the Tekmira press release from 22.Sept anymore, where they stated that "TKM-Ebola has been administered to a number of patients". Can someone provide a link to the official press release please?
RGDO....look out below....how's that trade working guys....dead cat no bounce yikes
Interesting article, trying to find some more articles. Kindly Provide me more sources so I can explore more about it.
Post a Comment